Aurobindo Pharma Limited vs Cipla Limited
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Cipla Limited is the larger company by market value: $12.3 B against $11.2 B for Aurobindo Pharma Limited, 1.1 times as much (market caps of Nov 20, 2026).
- Aurobindo Pharma Limited had more revenue: $3.6 B against $3.0 B for Cipla Limited, both in the year to March 2026.
- Cipla Limited earned more: net income of $419 M against $378 M for Aurobindo Pharma Limited.
- Cipla Limited keeps more of each dollar of sales: a net margin of 14.0% against 10.5% for Aurobindo Pharma Limited.
- Cipla Limited employs more people: 23,000 against 15,690 at Aurobindo Pharma Limited. Each employee brings in about $229,751 of revenue at Aurobindo Pharma Limited and $130,097 at Cipla Limited.
- On price to earnings, Aurobindo Pharma Limited trades at 29.5× and Cipla Limited at 29.4×: investors pay more for each dollar of Aurobindo Pharma Limited's profit.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Side by side
| Measure | Aurobindo Pharma Limited AUROPHARMA.NS · #2,011 in the world | Cipla Limited CIPLA.BO · #1,863 in the world |
|---|---|---|
| Profile | ||
| Country | 🇮🇳 India | 🇮🇳 India |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1986 | 1935 |
| Size | ||
| Market cap | $11.2 B | $12.3 B |
| Revenue | $3.6 B | $3.0 B |
| Net income | $378 M | $419 M▲ best |
| Employees | 15,690 | 23,000 |
| Valuation | ||
| P/E ratio | 29.5× | 29.4× |
| Price to sales | 3.1× | 4.1× |
| Price to book | 2.7× | 3.3× |
| Altman Z-score zone | — | — |
| Data as of | Market cap Nov 2026 | Market cap Nov 2026 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Aurobindo Pharma Limited or Cipla Limited?
Cipla Limited is the larger company by market value: $12.3 B against $11.2 B for Aurobindo Pharma Limited, 1.1 times as much (market caps of Nov 20, 2026).
Which makes more money, Aurobindo Pharma Limited or Cipla Limited?
Aurobindo Pharma Limited had more revenue: $3.6 B against $3.0 B for Cipla Limited, both in the year to March 2026. Cipla Limited earned more: net income of $419 M against $378 M for Aurobindo Pharma Limited.
Which is more profitable, Aurobindo Pharma Limited or Cipla Limited?
Cipla Limited keeps more of each dollar of sales: a net margin of 14.0% against 10.5% for Aurobindo Pharma Limited.
Which has more employees, Aurobindo Pharma Limited or Cipla Limited?
Cipla Limited employs more people: 23,000 against 15,690 at Aurobindo Pharma Limited. Each employee brings in about $229,751 of revenue at Aurobindo Pharma Limited and $130,097 at Cipla Limited.
Is Aurobindo Pharma Limited cheaper than Cipla Limited?
On price to earnings, Aurobindo Pharma Limited trades at 29.5× and Cipla Limited at 29.4×: investors pay more for each dollar of Aurobindo Pharma Limited's profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.
More about Aurobindo Pharma Limited
More about Cipla Limited
Sources#
Every figure on this page comes from these, with the date shown next to it.